Alpinvest Partners B.v. adds Dermira Inc (DERM) to its portfolio

Dermira Inc (DERM) : Alpinvest Partners B.v. added new position in Dermira Inc during the most recent quarter end. The investment management firm now holds 17,307 shares of Dermira Inc which is valued at $544,997 , the company said in a statement filed on Aug 10, 2016 with the SEC.Dermira Inc makes up approximately 0.91% of Alpinvest Partners B.v.’s portfolio.

Other Hedge Funds, Including , Blackrock Advisors boosted its stake in DERM in the latest quarter, The investment management firm added 95,784 additional shares and now holds a total of 420,188 shares of Dermira Inc which is valued at $13,231,720. Dermira Inc makes up approx 0.01% of Blackrock Advisors’s portfolio. Cable Hill Partners added DERM to its portfolio by purchasing 261 company shares during the most recent quarter which is valued at $8,420. Dermira Inc makes up approx 0.01% of Cable Hill Partners’s portfolio. Cable Hill Partners added DERM to its portfolio by purchasing 261 company shares during the most recent quarter which is valued at $8,420. Dermira Inc makes up approx 0.01% of Cable Hill Partners’s portfolio.California Public Employees Retirement System boosted its stake in DERM in the latest quarter, The investment management firm added 3,200 additional shares and now holds a total of 14,200 shares of Dermira Inc which is valued at $472,292. Quantbot Technologies Lp added DERM to its portfolio by purchasing 589 company shares during the most recent quarter which is valued at $19,590.

Dermira Inc opened for trading at $31.7 and hit $32.39 on the upside on Friday, eventually ending the session at $32, with a gain of 0.79% or 0.25 points. The heightened volatility saw the trading volume jump to 1,23,892 shares. Company has a market cap of $1,132 M.

Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on Jun 2, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .

Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *